Google enters the biotech stage with Calico

Google

     Google announced on Wednesday, September 18th that they were launching an ambitious, “mysterious” new venture named Calico. Calico is a company centered around combatting aging in its various forms. Google announced the company as, “a new company focused on health and well-being, in particular the challenge of aging and associated diseases.”

     There has been much speculation since the announcement on Wednesday about what the firm will actually do – after Google Health’s flop in 2012 it will be interesting to see which Calico will choose to go. Google CEO Larry Page summed up the general purpose behind Google’s interest in a health-related firm, in that “there’s tremendous potential for technology more generally to improve people’s lives.”

     Google named Art Levinson, former CEO of Genentech and Chairman of the board of Apple, Inc. as the CEO of Calico, who brings a wealth of experience to the new firm as both a biotech pioneer and successful businessman.  He served as the director of Google from 2004-2009 and has received various awards for his corporate leadership and management skills. His devotion to the development of pharmaceutical research and  advancement in the biotech industry bring an important perspective to a venture backed by Google, a firm with a little experience in the field.

    Without much credibility in the biotech arena and few details about Calico as of yet, it is nevertheless exciting to think about the possibilities Levinson and Co. can execute in the coming years.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: